Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505120 | 0.90 | S1PR4 (0.52) | HPGDALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL11370707 | 0.85 | LMNA (0.49) | TSHRHPGDALDH1A1LMNAMAPT | |
| SCHEMBL1505166 | 0.85 | GAA (0.60) | TSHRALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL12505380 | 0.84 | LMNA (0.48) | TSHRHPGDALDH1A1LMNAMAPT | |
| SCHEMBL4366901 | 0.82 | ALDH1A1 (0.44) | TSHRHPGDALDH1A1LMNAMAPT | |
| SCHEMBL8419947 | 0.82 | TSHR (0.53) | TSHRHPGDALDH1A1MAPTKDM4E | |
| SCHEMBL1505088 | 0.81 | GAA (0.56) | TSHRALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL15430834 | 0.80 | TSHR (0.50) | TSHRHPGDALDH1A1LMNAMAPT | |
| SCHEMBL6941866 | 0.79 | TSHR (0.53) | TSHRHPGDALDH1A1KDM4EKMT2A | |
| SCHEMBL7803468 | 0.79 | TSHR (0.43) | TSHRHPGDALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | TSHR 769/4885HPGD 2432/4885ALDH1A1 1286/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | TSHR 1011/4885HPGD 2426/4885ALDH1A1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.